Dexedrine Spansules · DIN 01924567 · 15 mg · extended release capsule
General benefitMarketed · checked November 18, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysODB senior: $100/program-year deductible
• Then up to $6.11 per prescription
Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription
Private plan not entered. Private-plan coverage, and how it coordinates with public programs, is not determined here; the Ontario public-program lines on this page remain conditional on the entered details and the program rules.
1 brand, same coverage
Dexedrine Spansules · DIN 01924567
Manufacturer: Paladin Pharma Inc.; listing date 2013-06-27
Health Canada: Marketed since 2026-02-25 · brand DEXEDRINE SPANSULE · ATC N06BA02 DEXAMFETAMINE · form Capsule (sustained-release) · route Oral · ingredients DEXTROAMPHETAMINE SULFATE 15 MG · company Knight therapeutics inc. · schedule Controlled drugs (cdsa i)
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 01924567)
Source record
DIN 01924567: Dexedrine Spansules
Raw flags: sec3=Y
Item: 282000009; group id 514; item number 1362; lccId None; manufacturer id PPI
Source form: SR Cap; strength: 15mg
Recorded listing: General benefit
Source prices (unrounded): $1.5222; ministry $0.9898
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=01924567
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=15210
Therapeutic Notes (formulary)
Notes: Patients greater than 6 years of age diagnosed with ADHD according to DSM-IV criteria and where symptoms are not due to other medical conditions which affect concentration, and who require 12-hour continuous coverage due to academic and/or psychosocial needs, and who meet the following:
1) Patients who demonstrate significant and problematic disruptive behaviour or who have problems with inattention that interfere with learning; AND
2) Prescribed by or in consultation with a specialist in pediatric psychiatry, pediatrics or a general practitioner with expertise in ADHD; AND
3) Have been tried on methylphenidate immediate release (IR) or methylphenidate slow release (SR) or Dexedrine IR, and have experienced unsatisfactory results due to poor symptom control, side effects, administrative barriers, or societal barriers.
Administrative barriers include:
- inability of a school to dose the child at lunch;
- the school lunch hour does not coincide with the dosing schedule;
- poor compliance with noon or afternoon doses;
- the patient is unable to swallow tablets.
Societal barriers include:
- the patient or patient's caregiver(s) has(have) a history of substance abuse or diversion of listed immediate-release alternatives;
- the patient or patient's caregiver(s) is/are at risk of substance abuse or diversion of listed immediate-release alternatives.
Interchangeable products
Teva-Dextroamphetamine SR · DIN 02448327 · $0.9898
Shortage status: not checked (no credentials)